

³ Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 58345

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

¹ Overexpression of CD155 associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in microenvironment of breast cancer

Wang RB *et al.* Overexpression of CD155 in breast cancer

¹ Rui-Bin Wang, Yu-Chen Li, Quan Zhou, Shu-Zhen Lv, Ke-Yu Yuan, Jiang-Ping Wu, Yan-Jie Zhao, Qing-Kun Song, Bin Zhu

Match Overview

1

Internet 1532 words
crawled on 20-Feb-2020
www.researchsquare.com

55%

2

Internet 27 words
crawled on 23-Jan-2020
www.hindawi.com

1%

3

Internet 15 words
crawled on 29-Mar-2020
f6publishing.blob.core.windows.net

1%



ALL

IMAGES

VIDEOS

31,400 Results

Any time ▾

Overexpression of an Immune Checkpoint (CD155) in Breast ...

<https://pubmed.ncbi.nlm.nih.gov/32411795>

Purpose: The immune checkpoint inhibitor is approved for breast cancer treatment, but the low expression of PD-L1 limits the immunotherapy. CD155 is another immune checkpoint protein in cancers and interacts with ligands to regulate immune microenvironment. This study is aimed at investigating the expression of CD155 and the association with prognosis and pathological features of breast cancer.

Cited by: 2

Author: Yu-Chen Li, Yu-Chen Li, Quan Zhou, Qing...

Publish Year: 2020

The immune suppressive factors CD155 and PD-L1 show ...

<https://www.sciencedirect.com/science/article/pii/S0090825820309896>

Jul 01, 2020 · Expression of CD155, TIGIT, PD-1, PD-L1, and other immune markers in HGSC was assessed by high-dimensional flow cytometry, multi-color histological imaging, and/or gene expression profiling. The prognostic significance of PVR/CD155 and CD274/PD-L1 expression was assessed bioinformatically in HGSC and 32 other cancers in The Cancer Genome Atlas.

Author: Julian Smazynski, Phineas T. Hamilto... Publish Year: 2020

Survival analysis with regard to PD-L1 and CD155 ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365950>

Jan 09, 2019 · PD-1/PD-L1 and TIGIT/CD155 were highly expressed, particularly in the cytoplasm and cell membrane of cancer cells and the matrix of tumor tissue (Fig. 2). The mean densities of PD-1, PD-L1, TIGIT and CD155 staining in the 60 SCLC samples from patients were 0.288, 0.316, 0.302 and 0.304, respectively (data not shown).

Cited by: 5

Author: Yaolin Xu, Guoyuan Cui, Zhongxiu Jiang, ...

Publish Year: 2019

Overexpression of an Immune Checkpoint (CD155) in Breast ...

<https://www.hindawi.com/journals/jir/2020/3948928> ▾

Purpose . The immune checkpoint inhibitor is approved for breast cancer treatment, but the low expression of PD-L1 limits the immunotherapy. CD155 is another immune checkpoint protein in cancers and interacts with ligands to regulate immune microenvironment. This study is aimed at investigating the expression of CD155 and the association with prognosis and pathological features of breast ...

国内版

国际版



Overexpression of CD155 associated with PD-1 and PD-L1 expressi



ALL

IMAGES

VIDEOS

59,700 Results

Any time ▼

Overexpression of an Immune Checkpoint (CD155) in Breast ...

<https://pubmed.ncbi.nlm.nih.gov/32411795>

Purpose: The **immune** checkpoint inhibitor is approved for **breast cancer** treatment, but the low **expression** of **PD-L1** limits the immunotherapy. **CD155** is another **immune** checkpoint protein in cancers and interacts with ligands to regulate **immune microenvironment**. This study is aimed at investigating the **expression of CD155** and the association with prognosis and pathological features of **breast cancer**.

Cited by: 3

Author: Yu-Chen Li, Yu-Chen Li, Quan Zhou, Qing-Ku...

Publish Year: 2020

Overexpression of an Immune Checkpoint (CD155) in Breast ...

<https://www.hindawi.com/journals/jir/2020/3948928> ▼

Purpose . The **immune** checkpoint inhibitor is approved for **breast cancer** treatment, but the low **expression** of **PD-L1** limits the immunotherapy. **CD155** is another **immune** checkpoint protein in cancers and interacts with ligands to regulate **immune microenvironment**. This study is aimed at investigating the **expression of CD155** and the association with prognosis and pathological features of **breast ...**

Cited by: 3

Author: Yu-Chen Li, Yu-Chen Li, Quan Zhou, Qing-Ku...

Publish Year: 2020



Overexpression of CD155 associated with PD-1 and PD-L1 expressic



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

58,600 Results

Any time ▾

Overexpression of an Immune Checkpoint (CD155) in Breast ...

<https://pubmed.ncbi.nlm.nih.gov/32411795>

Purpose: The **immune** checkpoint inhibitor is approved for **breast cancer** treatment, but the low **expression** of **PD-L1** limits the immunotherapy. **CD155** is another **immune** checkpoint protein in cancers and interacts with ligands to regulate **immune microenvironment**. This study is aimed at investigating the **expression of CD155** and the association with prognosis and pathological features of **breast cancer**.

Cited by: 3

Author: Yu-Chen Li, Yu-Chen Li, Quan Zhou, Qin...

Publish Year: 2020

Overexpression of an Immune Checkpoint (CD155) in Breast ...

<https://www.hindawi.com/journals/jir/2020/3948928> ▾

Purpose . The **immune** checkpoint inhibitor is approved for **breast cancer** treatment, but the low **expression** of **PD-L1** limits the immunotherapy. **CD155** is another **immune** checkpoint protein in cancers and interacts with ligands to regulate **immune microenvironment**. This study is aimed at investigating the **expression of CD155** and the association with prognosis and pathological features of **breast** ...

Cited by: 3

Author: Yu-Chen Li, Yu-Chen Li, Quan Zhou, Qin...

Publish Year: 2020

The immune suppressive factors CD155 and PD-L1 show ...

<https://www.sciencedirect.com/science/article/pii/S0090825820309896>

Jul 01, 2020 · **Expression of CD155**, TIGIT, **PD-1**, **PD-L1**, and other **immune** markers in HGSC was assessed by high-dimensional flow cytometry, multi-color histological imaging, and/or gene **expression** profiling. The prognostic significance of PVR/**CD155** and CD274/**PD-L1 expression** was assessed bioinformatically in HGSC and 32 other cancers in The **Cancer** Genome Atlas.

Author: Julian Smazynski, Phineas T. Hamilto...

Publish Year: 2020

Survival analysis with regard to PD-L1 and CD155 ...

<https://www.spandidos-publications.com/10.3892/ol.2019.9910> ▾

PD-1/PD-L1 and TIGIT/**CD155** were highly expressed, particularly in the cytoplasm and cell membrane of **cancer cells** and the matrix of **tumor** tissue . The mean densities of **PD-1**, **PD-L1**, TIGIT and **CD155**

Staining in the 60 SCLC samples from patients were 0.288, 0.316, 0.302 and ...